Hematology

The open-label, single-arm, multisite NEXICART-2 study will aim to enroll around 40 participants in total.

The associate professor of medicine at University of Colorado discussed how the field has shifted to support the growing use of CAR Ts and progress to come.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Catch up on any of the key FDA news stories you may have missed last month, with coverage highlights from the CGTLive® team.

Review top news and interview highlights from the week ending July 5, 2024.

The associate professor of medicine at University of Colorado discussed a post hoc analysis study on subgroup analyses of liso-cel response.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Patients in FUMANBA-2 received eque-cel after being ineligible for ASCT after 4 cycles of induction therapy.

The professor in residence for pediatrics at the Sickle Cell Center of Excellence at the University of California discussed gene therapy’s ongoing transformation of the treatment landscape.

Eight patients receiving either TSC-100 or TSC-101 have been disease-free for a median of 10 months of follow-up.

Review top news and interview highlights from the week ending June 28, 2024.

The associate professor of medicine at University of Colorado discussed data in the primary relapsed LBCL setting.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Review top news and interview highlights from the week ending June 21, 2024.

Data from up to 5 and 6 years of follow-up were presented at the 2024 EHA Congress.

In observance of World Sickle Cell Day, CGTLive brought together a variety of expert insights on navigating the rapidly expanding landscape of care for this inherited blood disorder.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The responses seen in the 9 patients included 3 complete responses (CRs), 2 very good partial responses, and 4 partial responses.

Earlier and prophylactic interventions have enabled low rates and severity of AEs in recent years of administration.

On the other hand, enhanced lymphodepletion increased incidence and severity of CRS and infection.

The scientist from Krembil Research Institute shared takeaways from the session she chaired.

There was a 98% (2.7% SD) mean reduction in monthly HAE attack rate through the patients’ most recent assessment.

Review top news and interview highlights from the week ending June 14, 2024.

The subgroup analysis also looked at safety outcomes.

The medical oncologist and clinical director of Myeloma Cellular Therapies at Dana-Farber Cancer Institute emphasized promising safety in patients with high-risk disease.